We are live on ! Find out more
Victory Capital Management

Victory Capital Management Portfolio holdings

AUM $156B
1-Year Est. Return 27.51%
This Fund
S&P 500
This Quarter Est. Return
+5.54%
1 Year Est. Return
+27.51%
3 Year Est. Return
+75.53%
5 Year Est. Return
+102.92%
10 Year Est. Return
+480.77%
AUM
$49.6B
AUM Growth
+$5.62B
Cap. Flow
+$2.56B
Cap. Flow %
5.15%
Top 10 Hldgs %
6.81%
Holding
1,885
New
111
Increased
738
Reduced
863
Closed
63

Top Sells

Rank Stock Value
1
INGR icon
Ingredion
INGR
+$85.6M
2
KEYS icon
Keysight
KEYS
+$83.3M
3
ATI icon
ATI
ATI
+$81.4M
4
KMT icon
Kennametal
KMT
+$66.6M
5
KDP icon
Keurig Dr Pepper
KDP
+$65.1M

Sector Composition

Rank Sector Weight
1 Financials 16.46%
2 Industrials 15.08%
3 Technology 14.03%
4 Consumer Discretionary 11.15%
5 Healthcare 8.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HOME
1751
DELISTED
At Home Group Inc.
HOME
$15K ﹤0.01%
2,304
-752,300
-100% -$13.3M
ESPR
1752
DELISTED
Esperion Therapeutics
ESPR
$13K ﹤0.01%
273
KFY icon
1753
Korn Ferry
KFY
$4.21B
$13K ﹤0.01%
317
-6
-2% -$273
QUOT
1754
DELISTED
Quotient Technology Inc
QUOT
$13K ﹤0.01%
1,199
-22
-2% -$223
EPRT icon
1755
Essential Properties Realty Trust
EPRT
$6.74B
$11K ﹤0.01%
+525
New +$10.7K
GLPI icon
1756
Gaming and Leisure Properties
GLPI
$12.7B
$11K ﹤0.01%
+275
New +$10.9K
HPP
1757
Hudson Pacific Properties
HPP
$786M
$11K ﹤0.01%
46
-140
-75% -$33.6K
BVH
1758
DELISTED
Bluegreen Vacations Holding Corporation
BVH
$11K ﹤0.01%
445
-9
-2% -$230
CLLS
1759
Cellectis
CLLS
$277M
$10K ﹤0.01%
660
DEI icon
1760
Douglas Emmett
DEI
$1.99B
$10K ﹤0.01%
260
-745
-74% -$30.5K
FOMX
1761
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$10K ﹤0.01%
4,125
LXRX icon
1762
Lexicon Pharmaceuticals
LXRX
$1.03B
$9K ﹤0.01%
1,505
CBAY
1763
DELISTED
Cymabay Therapeutics
CBAY
$9K ﹤0.01%
1,278
NVTR
1764
DELISTED
Nuvectra Corporation Common Stock
NVTR
$8K ﹤0.01%
2,334
BNGOW
1765
DELISTED
Bionano Genomics, Inc. Warrant
BNGOW
$6K ﹤0.01%
8,136
ABEO icon
1766
Abeona Therapeutics
ABEO
$364M
$5K ﹤0.01%
43
GMDA
1767
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$5K ﹤0.01%
1,000
SKT icon
1768
Tanger
SKT
$4.68B
$3K ﹤0.01%
195
-570
-75% -$10.3K
ENOV icon
1769
Enovis
ENOV
$1.81B
$1K ﹤0.01%
17
EXP icon
1770
Eagle Materials
EXP
$6.59B
$1K ﹤0.01%
8
-1
-11% -$88
THO icon
1771
Thor Industries
THO
$4.03B
$1K ﹤0.01%
16
ACRS icon
1772
Aclaris Therapeutics
ACRS
$772M
-102,251
Closed -$612K
AQST icon
1773
Aquestive Therapeutics
AQST
$476M
-5,000
Closed -$35K
ASMB icon
1774
Assembly Biosciences
ASMB
$503M
-46,867
Closed -$11.1M
AVT icon
1775
Avnet
AVT
$7.29B
-161,585
Closed -$7.01M

Similar funds

Victory Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Victory Capital Management held 1,885 positions worth $49.6B, up 13% from $44B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.

Victory Capital Management deployed $2.56B of net new capital in Q2 2019, opening 111 new positions and adding to 738 existing holdings. Its largest new stake was Goldman Sachs ActiveBeta US Large Cap Equity ETF: 3,081,520 shares worth $181M.

By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Ingredion, an estimated $85.6M trimmed.

  • Victory Capital Management's largest Q2 2019 buy was Goldman Sachs ActiveBeta US Large Cap Equity ETF: 3,081,520 shares worth $181M.
  • Victory Capital Management added most to KLA in Q2 2019, an estimated $151M increase.
  • Victory Capital Management's biggest Q2 2019 reduction was Ingredion, cutting an estimated $85.6M.
  • Victory Capital Management fully exited Teladoc Health in Q2 2019, selling an estimated $50.5M.
  • Victory Capital Management's ten largest holdings make up 6.8% of its $49.6B portfolio in Q2 2019.
  • Victory Capital Management opened 111 new positions and closed 63 in Q2 2019.
  • Victory Capital Management's portfolio value rose 13% quarter-over-quarter to $49.6B.

Based on Victory Capital Management's 13F filing for Q2 2019, filed 15 Aug 2019.